Next Article in Journal
Feature Papers in Population and Evolutionary Genetics and Genomics 2023: Unraveling Population Dynamics, Diversity, and Evolutionary Paths
Next Article in Special Issue
Resolving Discrepancies in Idylla BRAF Mutational Assay Results Using Targeted Next-Generation Sequencing
Previous Article in Journal
Intraspecific and Intrageneric Genomic Variation across Three Sedum Species (Crassulaceae): A Plastomic Perspective
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Communication

Paternally Inherited Noonan Syndrome Caused by a PTPN11 Variant May Exhibit Mild Symptoms: A Case Report and Literature Review

1
Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
2
Department of Laboratory Medicine, Jeonbuk National University Medical School and Hospital, Jeonju 54907, Republic of Korea
3
Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju 54907, Republic of Korea
*
Author to whom correspondence should be addressed.
Genes 2024, 15(4), 445; https://doi.org/10.3390/genes15040445
Submission received: 27 February 2024 / Revised: 28 March 2024 / Accepted: 28 March 2024 / Published: 31 March 2024
(This article belongs to the Special Issue Precision Medicine and Genetics)

Abstract

:
Background: Noonan syndrome (NS)/Noonan syndrome with multiple lentigines (NSML) is commonly characterized by distinct facial features, a short stature, cardiac problems, and a developmental delay of variable degrees. However, as many as 50% of individuals diagnosed with NS/NSML have a mildly affected parent or relative due to variable expressivity and possibly incomplete penetrance of the disorder, and those who are recognized to have NS only after a diagnosis are established in a more obviously affected index case. Methods: In order to collect intergenerational data reported from previous studies, electronic journal databases containing information on the molecular genetics of PTPN11 were searched from 2000 to 2022. Results: We present a case of a proband with a PTPN11 variant (c.1492C > T/p.Arg498Trp) inherited from an asymptomatic father, displaying only mild intellectual disability without classical symptoms of NS. Among our cases and the reported NS cases caused by the PTPN11 p.Arg498Trp variant, cardiac abnormalities (6/11), facial dysmorphism (7/11), skin pigmentation (4/11), growth problems (4/11), and sensorineural hearing loss (2/11) have been observed. NS/NSML patients with the PTPN11 p.Arg498Trp variant tend to exhibit relatively lower frequencies of skin pigmentation, facial dysmorphism and cardiac abnormalities and mild symptoms compared to those carrying any other mutated PTPN11. Conclusions: Paternally inherited NS/NSML caused by a PTPN11 p.Arg498Trp variant, including our cases, may exhibit relatively lower frequencies of abnormal features and mild symptoms. This could be ascribed to potential gene–gene interactions, gene–environment interactions, the gender and phenotype of the transmitting parent, or ethnic differences that influence the clinical phenotype.

1. Introduction

Noonan syndrome (NS)/Noonan syndrome with multiple lentigines (NSML) is commonly characterized by distinctive facial features, a short stature, cardiac problems, and developmental delay of variable degrees [1]. The molecular diagnosis of NS involves identifying heterozygous pathogenic variants in BRAF, KRAS, MAP2K1, MRAS, NRAS, PTPN11, RAF1, RASA2, RIT1, RRAS2, SOS1, or SOS2, inherited in an autosomal dominant manner [2,3]. Variants associated with NS in SHP2 display elevated phosphatase activity, whereas variants linked to NSML result in reduced catalytic activity [4,5]. Among them, PTPN11 plays a regulatory role in neurogenesis, influencing processes such as neuronal differentiation, neurite outgrowth and migration, as well as the proliferation and maturation of oligodendrocytes [6,7]. Variants in PTPN11 may contribute to the manifestation of neurodevelopmental disorders observed in some patients with NS or NSML. However, as many as 50% of individuals diagnosed with NS/NSML have a mildly affected parent or relative due to variable expressivity and possibly incomplete penetrance of the disorder, and those who are recognized to have NS only after a diagnosis are established in a more obviously affected index case. In animal models of NS, variants in PTPN11 have been associated with deficits in intention, hyperactivity, memory impairment, and learning disabilities [8,9]. Such alterations in brain development can lead to developmental deficits associated with NS/NSML. Variants in PTPN11 are responsible for RASopathies, including NS and NSML, with a prevalence of up to 50% [10]. To date, several missense variants of PTPN11 have been reported, primarily situated in the PTP domain, demonstrating a dominant negative effect: p. Tyr279Cys/Ser, p.Ala461Thr/Ser, p.G464A, p.Thr468Met/Pro, p.Arg498Leu/Trp, p.Gln506Pro, and p.Gln510Glu/Gly [11]. Two of these variants (p.Trp279Cys and p.Thr468Met) are prevalent, accounting for about two-thirds of cases.
In this context, we present a case of a proband with a PTPN11 variant (c.1492C>T/p.Arg498Trp) inherited from an asymptomatic father, displaying only mild intellectual disability (ID) without other associated symptoms of RASopathy. The PTPN11 p.Arg498Trp variant has previously been reported in patients with NS/NSML, exhibiting a spectrum of clinical features, including multiple lentigines, cardiac abnormalities, facial dysmorphism, and variable degrees of cognitive impairments [12,13,14]. The collective phenotypes reported in previous studies, including our case, contribute to an enhanced understanding of PTPN11 variants. No single clinical feature was shown across the previous reports; however, this family revealed few symptoms contributing to an enhanced understanding of PTPN11 variants.

2. Materials and Methods

2.1. Genetic Testing

Considering the short stature and ID observed in the proband, we pursued sequential genetic testing for various familial short stature and/or ID disorders. These included conventional karyotyping, an FMR1 (CGG)n triplet repeat test, and chromosomal microarray analysis. However, no pathogenic alterations were identified in these initial genetic tests. Subsequently, we employed a clinical exome sequencing utilizing the Celemics G-Mendeliome Clinical Exome Sequencing Panel (Celemics, Inc., Seoul, Republic of Korea), which includes a wide range of 7000 genes associated with clinically significant Mendelian genetic diseases, even including all clinically significant regions. Massively parallel sequencing was carried out with the DNBSEQ-G400RS High-throughput Sequencing Set and DNBSEQ-G400 sequencer (MGI Tech Co. Ltd., Shenzhen, China). The interpretation of pathogenic variants followed the standards and guidelines set by the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP).

2.2. Literature Review of PTPN11 p.Arg498Trp

In order to collect intergenerational data reported from previous studies, electronic journal databases, including KoreaMed (http://koreamed.org, accessed on 10 November 2023) and PubMed (https://www.ncbi.nlm.nih.gov/pubmed, accessed on 10 November 2023), containing information on the molecular genetics of PTPN11, were searched from 2000 to 2022. The following terms were used in search strategies: PTPN11 mutation, p.Arg498Trp, Rasopathies, LEOPARD syndrome, and Noonan syndrome. All related citations were retrieved to find other relevant articles that were not identified in the initial research. The literature search included Korean as well as English articles. Only reported cases with well-documented relevant information about the gender, variant type of the PTPN11 gene, and/or the detailed phenotypes of the transmitting parent and the affected child were included. After a literature search related to NS/NSML with PTPN11 p.Arg498Trp [12,13,15,16,17,18,19], 39 parent–child matched pairs with information about each gender, the p.Arg498Trp of the PTPN11 gene, and/or the NS/NSML’s clinical phenotypes were included in this study.

3. Patient Description

3.1. The Proband

The proband (II-1 in Figure 1a) is a 6-year-old boy with a short stature and ID, referred to the Department of Pediatric Neurology, Daejeon St. Mary’s hospital (Daejeon, Republic of Korea) for medical evaluation. He was born to nonconsanguineous, healthy Korean parents at 37 weeks of gestational age through normal vaginal delivery. At birth, his body weight was 2.5 kg (25th percentile), and his height was 46 cm (25th percentile). He is the first child, and the pregnancy was uneventful, with no family history of neurodevelopmental disorders. During the physical examination, no facial dysmorphism or skeletal abnormalities were observed, and there were no signs of lentigines or café-au-lait spots. The neonatal-to-toddler period was unremarkable; he began speaking at 12 months and walked independently at 13 months. However, issues with reading, writing, and social communication arose after entering kindergarten. His intellectual quotient (IQ) was estimated at 60 at 6 years old, indicating mild ID on the Wechsler Intelligence Scale for Children. Despite mild learning disabilities, he attended a preschool for normal children but received specialized education to enhance academic skills and social communication. At the age of 6, his height was 107.5 cm (5th percentile), and his body weight was 18.5 kg (10th percentile). His expected mid-parental height ranged from the 10th to the 20th percentile (169 cm), indicating a constitutional growth delay. Both hearing (right 6 dB and left 5 dB) and visual acuity were within the normal range (Figure 1b). Brain magnetic resonance imaging showed no structural abnormalities and appropriate myelination for the patient’s age, and spine X-ray revealed a normal structure with no apparent abnormalities (Figure 1c). Electrocardiography and echocardiogram results were also normal. Laboratory tests, including thyroid function, growth hormone, insulin-like growth factor (IGF)-I, IGF-binding protein 3, and metabolites, fell within the normal ranges. A wrist X-ray taken at the age of 6 indicated a bone age delayed to that of a 5-year-old child. Analysis of the peripheral blood smear revealed normal morphologies and counts, including white blood cells, platelets, and red blood cells. Clotting time tests, such as prothrombin time, activated partial thromboplastin time, and bleeding time, were performed and yielded results within the normal range. Urine analysis and a kidney sonogram yielded normal results without structural abnormalities. The skin condition, including color and texture, appeared to be within normal parameters. Conventional karyotyping revealed a normal male karyotype, and the FMR1 (CGG)n triplet repeat test was negative. Chromosomal microarray analysis showed no copy number variations.
Then, the clinical exome sequencing was sequentially performed, and a heterozygous pathologic c.1492C > T/p.Arg498Trp of the PTPN11 gene was the best candidate as the cause of the short stature and ID in the proband (Reference transcript ID: NM_002834.4). The clinical presentation of the proband was partially consistent with the PTPN11 variant, indicative of Noonan syndrome 1 (OMIM # 163950), presenting with short stature, facial dysmorphism, and a wide spectrum of congenital heart defects. Sanger sequencing confirmed the segregation of the PTPN11 p.Arg498Trp variant with the phenotype and established the autosomal dominant status of the heterozygous variant in both his father and sibling (Figure 2a). Protein structure analysis using AlphaFold (https://alphafold.ebi.ac.uk/; accessed on 16 March 2024) showed very high per-residue confidence scores (pLDDT) of 97.66 for the PTPN11 p.Arg498 residue highlighted in the pink box (Figure 2b).

3.2. The Proband’s Sibling

We assessed the proband’s sibling (II-2 in Figure 1a) for the first time when she was 4 years old. She was born at 37 weeks gestation, with a weight of 2450 g (25th percentile). At the age of 4, her height measured 90 cm (5–10th percentile), and her weight was 15 kg (5–10th percentile). Her expected mid-parental height is 156.5 cm (5–10th percentile). She exhibited normal intelligence, with an IQ of 100, and had no facial dysmorphism. An echocardiogram and electrocardiography were conducted, and the results were within the normal range. Visual acuity and auditory function appeared to be normal. Bone age assessment via wrist X-ray and hormonal level evaluations suggested a constitutional growth delay. Laboratory tests, including thyroid hormone levels and a skeletal survey, revealed no abnormalities. She attended a kindergarten for normal children and did not exhibit any medical problems.

3.3. The Proband’s Father

The proband’s father (I-1 in Figure 1a) experienced a completely normal development from birth to adolescence, with no reported learning difficulties. He successfully completed his college education without any abnormalities and is currently employed in the storage and delivery of goods. His height measured 163 cm (5th percentile), indicating familial growth delay. He maintains a good health without dysmorphism or deformities, and both echocardiogram and laboratory findings did not reveal any abnormalities.

4. Discussion

Many disorders present as autosomal dominant Mendelian traits and display a broad spectrum of phenotypes associated with factors such as penetrance, dominance, expressivity, and age-of-onset. Several hypotheses have been proposed to explain interfamilial and intra-familial phenotypic diversities in the context of the same gene variants. These include allelic variation, genetic backgrounds, ethnic origin, modifier genes, random mono-allelic expression, genetic compensation, environmental factors, and complex genetic and environmental interplay. Individual epigenetic variation is an important determinant of a range of clinical features [20]. Perturbation of a particular gene’s function in a pathway may alter the expression of other genes within the network, thereby influencing overall health [21]. Although many individuals with autosomal dominant NS have a de novo pathogenic variant, in 30%–75% of families, an affected parent is identified. NS/NSML can be diagnosed in a patient presenting with multiple lentigines and at least two other clinical features, such as cardiac problems, growth delay/short stature, facial dysmorphism, and pectus deformity [22]. Virtually all patients exhibit a dysmorphic face and multiple lentigines, with approximately 85% experiencing cardiac problems, including hypertrophic cardiomyopathy and pulmonary valve stenosis [23,24]. Growth delay leading to short stature is observed in more than 50% of patients, with heights falling below the 25th percentile for their age. Other clinical characteristics include sensorineural hearing loss (approximately 20%), ID (around 30%, typically in mild forms), and abnormal electrocardiography (seen in approximately 25% of cases) [25,26]. A literature review of NS patients with PTPN11 p.Arg498Trp found that eight cases were genetically confirmed by genetic test [3,12,13,16,17,18]. Detailed clinical manifestations reported in individuals carrying the PTPN11 p.Arg498Trp variant are summarized in Table 1.
In our family, the only common symptom observed was growth abnormalities (constituting constitutional growth delay and short stature), with other features such as cardiac problems and facial dysmorphism not co-existing. The proband exhibited mild ID and short stature without the typical characteristics of NS, which were inherited from his father, who had a normal intelligence and short stature. Among our cases and reported NS caused by the PTPN11 p.Arg498Trp variant, cardiac abnormalities (6/11), facial dysmorphism (7/11), skin pigmentation (4/11), growth problems (5/11), and sensorineural hearing loss (2/11) have been observed. Compared to PTPN11 variants in other locations [3,12,13,15,16,17,18,19], NS/NSML patients with the PTPN11 p.Arg498Trp variant tend to exhibit relatively lower frequencies of skin pigmentation, facial dysmorphism, and cardiac abnormalities and mild symptoms, compared to those carrying any other mutated PTPN11 (Figure 3), even though no statistically significant differences were observed, likely due to the considerable discrepancy in sample sizes when applying Pearson’s chi-squared or Fisher’s exact test.
Src-homology-2 (SH2) domain-containing protein-tyrosine phosphatase 2 (SHP2) is comprised of a catalytic protein-tyrosine phosphatase (PTP) domain that facilitates its association with signaling pathways [27]. Individual PTPN11 variants exhibit specificity to each syndrome, with opposite effects on catalysis, yet all promote SHP2’s interaction with signaling partners. Mutations in the gain-of-function (GF) region of PTPN11, encoding the SHP2, are responsible for NS, primarily located at the interface between the N-terminal SH2 and PTP domains. These mutations alter residues involved in the autoinhibitory interaction, making the molecule prone to assuming an open conformation, thereby increasing the constitutive catalytic activity of the phosphatase [27]. On the other hand, reported dominant negative (DN) mutations of SHP2 are located solely within the PTP domain, near the substrate binding or catalytic sites of SHP2. These mutations have been shown to decrease phosphatase activity, resulting in NSML due to the DN effect [27]. PTPN11 variants causing NS lead to SHP2’s GF and enhance RAS/MARK signaling [1].
On the other hand, PTPN11 variants resulting in NSML lead to a reduction in the catalytic activity of the phosphate [22]. While NS and NSML share numerous clinical features, NSML has often been considered a variant of NS. However, the presence of ML as a definitive sign of NSML is infrequent in NS, and less penetrant NS features, such as a web-like neck, skeletal abnormalities, and hematological abnormalities, do not manifest in NSML [28]. Despite the similarity in phenotype, the precise differences in biochemical effects are not well-established. Yu et al. [29,30] reported that NSML-causing PTPN11 variants not only result in reduced catalytic activity but also an increase in binding affinity/responsiveness, potentially contributing to overlapping clinical features. Particularly, members of the Spanish family carrying p.Thr357Met did not exhibit any apparent features fitting NSML or within the phenotypic spectrum of RASopathies. These findings reinforce the fact that the aberrant signal transduction resulting from PTPN11 variants cannot be solely attributed to catalytic activity but necessitates enhanced binding of the phosphatase to signaling partners [31]. In our NS family with the PTPN11 p.Arg498Trp variant, the proband exhibited ID and short stature without the typical characteristics of NS, and he inherited the variant from his father, who has normal intelligence. In another case report featuring the PTPN11 p.Arg498Trp variant [32], a 9-year-old Korean boy exhibited a mild attention deficit and short stature, lacking typical manifestations such as facial dysmorphism, congenital heart disease, and chest deformities. Although his father also had a short stature, he did not exhibit symptoms suggestive of NS/NSML. Disparities based on gender, ethnicity, and environmental factors may potentially manifest inter-individually and within families. Moreover, in both the proband and his father in an American family carrying the PTPN11 p.Arg498Trp variant, the proband, a 4-year-old boy with congenital profound deafness, underwent a comprehensive clinical re-evaluation, revealing minor craniofacial features that did not meet the diagnostic criteria for NS or NSML. The father, who was not available for clinical evaluation, denied having hearing loss and lentigines [13]. In a large-scale study of the clinical presentation and prevalence of lymphatic anomalies in patients with NS, patients with sporadic NS (16/40) have a high predisposition for developing lymphatic anomalies during life, compared to inherited NS (3/17, paternally inherited 1/6 and maternally inherited 2/11) [33].
Highlighting the phenotypic variability within families is crucial, especially when an affected family member has encountered severe cardiac or neurodevelopmental issues. The penetrance of NS in cases with PTPN11 variants is nearly complete, with only one reported case of incomplete penetrance [34]. Variants were identified in 59% of individuals with familial NS, while only 37% of individuals with sporadic NS showed such defects. This statistically significant difference in PTPN11 variant prevalence (p < 0.02) suggests that the additional gene or genes responsible for NS may contribute to incomplete penetrance or have more significant adverse effects on fertility than PTPN11 [35]. Additionally, it is crucial to emphasize that the variant prevalence detected in any NS cohort is sensitive to its composition in terms of the relative abundance of sporadic and familial cases. In instances where a parent is affected with NS and bears a PTPN11 variant, a sex-ratio bias is observed among offspring inheriting the defect [36]. This bias favors males by a factor of 2:1, and no sex-ratio distortion is noted among unaffected offspring. The available data suggest that this bias is linked to sex-specific developmental effects of PTPN11 variants, favoring the survival of affected male embryos compared to female ones. Due to the limited number of familial cases of NS not associated with PTPN11 variants, a systematic examination of sex-ratio bias in that genetic context has not been conducted.

5. Conclusions

Paternally inherited NS/NSML caused by a PTPN11 p.Arg498Trp variant, including our cases, may exhibit relatively lower frequencies of abnormal features and mild symptoms. This could be ascribed to potential gene–gene interactions, gene–environment interactions, the gender and phenotype of the transmitting parent, or ethnic differences that influence the clinical phenotype. This study contributes to an understanding of the PTPN11 p.Arg498Trp variant causing NS/NSML; further research is needed to comprehend the phenotypical variability, ranging from asymptomatic or very mild symptoms without key manifestations to typical NS/NSML.

Author Contributions

Conceptualization, J.Y.H.; methodology, J.P.; software, J.P.; validation, J.Y.H.; formal analysis, J.Y.H.; investigation, J.Y.H.; resources, J.Y.H.; data curation, J.Y.H.; writing—original draft preparation, J.Y.H. and J.P.; writing—review and editing, J.Y.H. and J.P.; visualization, J.Y.H. and J.P.; supervision, J.Y.H.; project administration, J.Y.H.; funding acquisition, J.Y.H. All authors have read and agreed to the published version of the manuscript.

Funding

The authors wish to acknowledge the financial support of the Catholic Medical Center Research Foundation made in the program year of 2023. This work was supported by a grant from the National Research Foundation of Korea (NRF) funded by the Korean government (Ministry of Science and ICT (MSIT): 2021R1F1A1063568). This paper was supported by the Fund of Biomedical Research Institute, Jeonbuk National University Hospital.

Institutional Review Board Statement

This study was approved by the Institutional Review Board (IRB) of the Catholic University of Korea (Approval number: DC23ZASI0004; Date of approval: 17 January 2023).

Informed Consent Statement

Written informed consent was obtained from the parents on behalf of their child and for the publication of any potentially identifiable images or data included in this article, as well as for the use of the clinical data of the probands’ families.

Data Availability Statement

Data are contained within the article.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Roberts, A.E.; Allanson, J.E.; Tartaglia, M.; Gelb, B.D. Noonan syndrome. Lancet 2013, 381, 333–342. [Google Scholar] [CrossRef]
  2. Sarkozy, A.; Carta, C.; Moretti, S.; Zampino, G.; Digilio, M.C.; Pantaleoni, F.; Scioletti, A.P.; Esposito, G.; Cordeddu, V.; Lepri, F.; et al. Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: Molecular diversity and associated phenotypic spectrum. Hum. Mutat. 2009, 30, 695–702. [Google Scholar] [CrossRef]
  3. Digilio, M.C.; Lepri, F.; Baban, A.; Dentici, M.L.; Versacci, P.; Capolino, R.; Ferese, R.; De Luca, A.; Tartaglia, M.; Marino, B.; et al. RASopathies: Clinical Diagnosis in the First Year of Life. Mol. Syndromol. 2011, 1, 282–289. [Google Scholar] [CrossRef]
  4. Fragale, A.; Tartaglia, M.; Wu, J.; Gelb, B.D. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation. Hum. Mutat. 2004, 23, 267–277. [Google Scholar] [CrossRef] [PubMed]
  5. Kontaridis, M.I.; Swanson, K.D.; David, F.S.; Barford, D.; Neel, B.G. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J. Biol. Chem. 2006, 281, 6785–6792. [Google Scholar] [CrossRef]
  6. Huang, Y.S.; Cheng, C.Y.; Chueh, S.H.; Hueng, D.Y.; Huang, Y.F.; Chu, C.M.; Wu, S.T.; Tai, M.C.; Liang, C.M.; Liao, M.H.; et al. Involvement of SHP2 in focal adhesion, migration and differentiation of neural stem cells. Brain Dev. 2012, 34, 674–684. [Google Scholar] [CrossRef]
  7. Ishii, A.; Fyffe-Maricich, S.L.; Furusho, M.; Miller, R.H.; Bansal, R. ERK1/ERK2 MAPK signaling is required to increase myelin thickness independent of oligodendrocyte differentiation and initiation of myelination. J. Neurosci. 2012, 32, 8855–8864. [Google Scholar] [CrossRef] [PubMed]
  8. Lee, Y.S.; Ehninger, D.; Zhou, M.; Oh, J.Y.; Kang, M.; Kwak, C.; Ryu, H.H.; Butz, D.; Araki, T.; Cai, Y.; et al. Mechanism and treatment for learning and memory deficits in mouse models of Noonan syndrome. Nat. Neurosci. 2014, 17, 1736–1743. [Google Scholar] [CrossRef] [PubMed]
  9. Kusakari, S.; Saitow, F.; Ago, Y.; Shibasaki, K.; Sato-Hashimoto, M.; Matsuzaki, Y.; Kotani, T.; Murata, Y.; Hirai, H.; Matsuda, T.; et al. Shp2 in forebrain neurons regulates synaptic plasticity, locomotion, and memory formation in mice. Mol. Cell Biol. 2015, 35, 1557–1572. [Google Scholar] [CrossRef]
  10. Athota, J.P.; Bhat, M.; Nampoothiri, S.; Gowrishankar, K.; Narayanachar, S.G.; Puttamallesh, V.; Farooque, M.O.; Shetty, S. Molecular and clinical studies in 107 Noonan syndrome affected individuals with PTPN11 mutations. BMC Med. Genet. 2020, 21, 50. [Google Scholar] [CrossRef]
  11. Martínez-Quintana, E.; Rodríguez-González, F. LEOPARD Syndrome: Clinical Features and Gene Mutations. Mol. Syndromol. 2012, 3, 145–157. [Google Scholar] [CrossRef]
  12. Sarkozy, A.; Conti, E.; Digilio, M.C.; Marino, B.; Morini, E.; Pacileo, G.; Wilson, M.; Calabrò, R.; Pizzuti, A.; Dallapiccola, B. Clinical and molecular analysis of 30 patients with multiple lentigines LEOPARD syndrome. J. Med. Genet. 2004, 41, e68. [Google Scholar] [CrossRef]
  13. Bademci, G.; Cengiz, F.B.; Foster Ii, J.; Duman, D.; Sennaroglu, L.; Diaz-Horta, O.; Atik, T.; Kirazli, T.; Olgun, L.; Alper, H.; et al. Variations in Multiple Syndromic Deafness Genes Mimic Non-syndromic Hearing Loss. Sci. Rep. 2016, 6, 31622. [Google Scholar] [CrossRef]
  14. Johnson, E.M.; Ishak, A.D.; Naylor, P.E.; Stevenson, D.A.; Reiss, A.L.; Green, T. PTPN11 Gain-of-Function Mutations Affect the Developing Human Brain, Memory, and Attention. Cereb. Cortex 2019, 29, 2915–2923. [Google Scholar] [CrossRef]
  15. Digilio, M.C.; Sarkozy, A.; de Zorzi, A.; Pacileo, G.; Limongelli, G.; Mingarelli, R.; Calabrò, R.; Marino, B.; Dallapiccola, B. LEOPARD syndrome: Clinical diagnosis in the first year of life. Am. J. Med. Genet. A 2006, 140, 740–746. [Google Scholar] [CrossRef]
  16. Kratz, C.P.; Nathrath, M.; Freisinger, P.; Dressel, P.; Assmuss, H.P.; Klein, C.; Yoshimi, A.; Burdach, S.; Niemeyer, C.M. Lethal proliferation of erythroid precursors in a neonate with a germline PTPN11 mutation. Eur. J. Pediatr. 2006, 165, 182–185. [Google Scholar] [CrossRef] [PubMed]
  17. Du-Thanh, A.; Cave, H.; Bessis, D.; Puso, C.; Guilhou, J.J.; Dereure, O. A novel PTPN11 gene mutation in a patient with LEOPARD Syndrome. Arch. Dermatol. 2007, 143, 1210–1211. [Google Scholar] [CrossRef] [PubMed]
  18. Limongelli, G.; Sarkozy, A.; Pacileo, G.; Calabrò, P.; Digilio, M.C.; Maddaloni, V.; Gagliardi, G.; Di Salvo, G.; Iacomino, M.; Marino, B.; et al. Genotype-phenotype analysis and natural history of left ventricular hypertrophy in LEOPARD syndrome. Am. J. Med. Genet. A 2008, 146a, 620–628. [Google Scholar] [CrossRef] [PubMed]
  19. Edwards, J.J.; Martinelli, S.; Pannone, L.; Lo, I.F.; Shi, L.; Edelmann, L.; Tartaglia, M.; Luk, H.M.; Gelb, B.D. A PTPN11 allele encoding a catalytically impaired SHP2 protein in a patient with a Noonan syndrome phenotype. Am. J. Med. Genet. A 2014, 164a, 2351–2355. [Google Scholar] [CrossRef]
  20. Waterland, R.A.; Michels, K.B. Epigenetic epidemiology of the developmental origins hypothesis. Annu. Rev. Nutr. 2007, 27, 363–388. [Google Scholar] [CrossRef]
  21. Davidson, E.; Levin, M. Gene regulatory networks. Proc. Natl. Acad. Sci. USA 2005, 102, 4935. [Google Scholar] [CrossRef] [PubMed]
  22. Carcavilla, A.; Santomé, J.L.; Pinto, I.; Sánchez-Pozo, J.; Guillén-Navarro, E.; Martín-Frías, M.; Lapunzina, P.; Ezquieta, B. LEOPARD syndrome: A variant of Noonan syndrome strongly associated with hypertrophic cardiomyopathy. Rev. Esp. Cardiol. (Engl. Ed.) 2013, 66, 350–356. [Google Scholar] [CrossRef] [PubMed]
  23. Sarkozy, A.; Digilio, M.C.; Dallapiccola, B. Leopard syndrome. Orphanet J. Rare Dis. 2008, 3, 13. [Google Scholar] [CrossRef] [PubMed]
  24. Tartaglia, M.; Gelb, B.D.; Zenker, M. Noonan syndrome and clinically related disorders. Best. Pract. Res. Clin. Endocrinol. Metab. 2011, 25, 161–179. [Google Scholar] [CrossRef] [PubMed]
  25. Palit, A.; Inamadar, A.C. RASopathies: Dermatologists’ viewpoints. Indian J. Dermatol. Venereol. Leprol. 2022, 88, 452–463. [Google Scholar] [CrossRef] [PubMed]
  26. Rauen, K.A. The RASopathies. Annu. Rev. Genom. Hum. Genet. 2013, 14, 355–369. [Google Scholar] [CrossRef] [PubMed]
  27. Hijikata, A.; Tsuji, T.; Shionyu, M.; Shirai, T. Decoding disease-causing mechanisms of missense mutations from supramolecular structures. Sci. Rep. 2017, 7, 8541. [Google Scholar] [CrossRef] [PubMed]
  28. Rauen, K.A. Defining RASopathy. Dis. Model. Mech. 2022, 15, dmm049344. [Google Scholar] [CrossRef] [PubMed]
  29. Yu, Z.H.; Xu, J.; Walls, C.D.; Chen, L.; Zhang, S.; Zhang, R.; Wu, L.; Wang, L.; Liu, S.; Zhang, Z.Y. Structural and mechanistic insights into LEOPARD syndrome-associated SHP2 mutations. J. Biol. Chem. 2013, 288, 10472–10482. [Google Scholar] [CrossRef]
  30. Yu, Z.H.; Zhang, R.Y.; Walls, C.D.; Chen, L.; Zhang, S.; Wu, L.; Liu, S.; Zhang, Z.Y. Molecular basis of gain-of-function LEOPARD syndrome-associated SHP2 mutations. Biochemistry 2014, 53, 4136–4151. [Google Scholar] [CrossRef]
  31. Lorca, R.; Pannone, L.; Cuesta-Llavona, E.; Bocchinfuso, G.; Rodríguez-Reguero, J.; Carpentieri, G.; Hernando, I.; Flex, E.; Tartaglia, M.; Coto, E.; et al. Compound heterozygosity for PTPN11 variants in a subject with Noonan syndrome provides insights into the mechanism of SHP2-related disorders. Clin. Genet. 2021, 99, 457–461. [Google Scholar] [CrossRef] [PubMed]
  32. Kim, Y.S.; Lee, S.; Ki, C.; Park, M.J. Familial Noonan Syndrome Confirmed by PTPN11 Gene Test. Ann. Pediatr. Endocrinol. Metab. 2008, 13, 117–121. [Google Scholar]
  33. Swarts, J.W.; Kleimeier, L.E.R.; Leenders, E.; Rinne, T.; Klein, W.M.; Draaisma, J.M.T. Lymphatic anomalies during lifetime in patients with Noonan syndrome: Retrospective cohort study. Am. J. Med. Genet. A 2022, 188, 3242–3261. [Google Scholar] [CrossRef]
  34. Tartaglia, M.; Kalidas, K.; Shaw, A.; Song, X.; Musat, D.L.; van der Burgt, I.; Brunner, H.G.; Bertola, D.R.; Crosby, A.; Ion, A.; et al. PTPN11 mutations in Noonan syndrome: Molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am. J. Hum. Genet. 2002, 70, 1555–1563. [Google Scholar] [CrossRef] [PubMed]
  35. Tartaglia, M.; Gelb, B.D. Noonan syndrome and related disorders: Genetics and pathogenesis. Annu. Rev. Genomics Hum. Genet. 2005, 6, 45–68. [Google Scholar] [CrossRef]
  36. Tartaglia, M.; Cordeddu, V.; Chang, H.; Shaw, A.; Kalidas, K.; Crosby, A.; Patton, M.A.; Sorcini, M.; van der Burgt, I.; Jeffery, S.; et al. Paternal germline origin and sex-ratio distortion in transmission of PTPN11 mutations in Noonan syndrome. Am. J. Hum. Genet. 2004, 75, 492–497. [Google Scholar] [CrossRef]
Figure 1. Pedigree and segregation analysis. (a) In generation I, the proband’s father has the trait. In generation II, the proband (indicated by black arrow) carrying a heterozygous PTPN11 c.1492C > T/p.Arg498Trp variant in an autosomal dominant inheritance and his family members. Roman numerals (I and II) indicate the generation. Blue filled box indicates short stature and black filled box indicates intellectual disability. (b) Both hearing (right 6 dB and left 5 dB) was within the normal range. (c) Brain magnetic resonance imaging showed no structural abnormalities and appropriate myelination for the patient’s age, and spine X-ray revealed a normal structure with no apparent abnormalities.
Figure 1. Pedigree and segregation analysis. (a) In generation I, the proband’s father has the trait. In generation II, the proband (indicated by black arrow) carrying a heterozygous PTPN11 c.1492C > T/p.Arg498Trp variant in an autosomal dominant inheritance and his family members. Roman numerals (I and II) indicate the generation. Blue filled box indicates short stature and black filled box indicates intellectual disability. (b) Both hearing (right 6 dB and left 5 dB) was within the normal range. (c) Brain magnetic resonance imaging showed no structural abnormalities and appropriate myelination for the patient’s age, and spine X-ray revealed a normal structure with no apparent abnormalities.
Genes 15 00445 g001
Figure 2. Segregation and protein structure analysis. (a) Sanger sequencing confirmed heterozygous PTPN11 c.1492C>T/p.Arg498Trp variant of paternal origin in the proband (II-1) (Reference transcript ID: NM_002834.4). Each PTPN11 variant is emphasized with the red dot. (b) Protein structure analysis using AlphaFold showed very high per-residue confidence scores (pLDDT) of 97.66 for PTPN11 p.Arg498 residue highlighted in pink box. Blue, sky blue, yellow, and orange color regions indicate pLDDT values greater than 90, between 70 and 90, between 50 and 70, and less than 50, respectively. Abbreviation: N−SH2, N-terminal Src-homology-2 domain; C−SH2, C-terminal Src-homology-2 domain, PTP, protein tyrosine phosphatase.
Figure 2. Segregation and protein structure analysis. (a) Sanger sequencing confirmed heterozygous PTPN11 c.1492C>T/p.Arg498Trp variant of paternal origin in the proband (II-1) (Reference transcript ID: NM_002834.4). Each PTPN11 variant is emphasized with the red dot. (b) Protein structure analysis using AlphaFold showed very high per-residue confidence scores (pLDDT) of 97.66 for PTPN11 p.Arg498 residue highlighted in pink box. Blue, sky blue, yellow, and orange color regions indicate pLDDT values greater than 90, between 70 and 90, between 50 and 70, and less than 50, respectively. Abbreviation: N−SH2, N-terminal Src-homology-2 domain; C−SH2, C-terminal Src-homology-2 domain, PTP, protein tyrosine phosphatase.
Genes 15 00445 g002
Figure 3. Different frequencies (%) of clinical features in Noonan syndrome (NS) or Noonan syndrome with multiple lentigines (NSML) carrying the PTPN11 p.Arg498Trp variant compared to those with any other mutated PTPN11. DD/ID, developmental disability and intellectual disability.
Figure 3. Different frequencies (%) of clinical features in Noonan syndrome (NS) or Noonan syndrome with multiple lentigines (NSML) carrying the PTPN11 p.Arg498Trp variant compared to those with any other mutated PTPN11. DD/ID, developmental disability and intellectual disability.
Genes 15 00445 g003
Table 1. Detailed clinical manifestations reported in individuals carrying PTPN11 p.Arg498Trp variant.
Table 1. Detailed clinical manifestations reported in individuals carrying PTPN11 p.Arg498Trp variant.
ReferencesThis ReportThis ReportThis ReportBademci et al. [13]Edwards et al. [19]Limongelli et al. [18]Du-Thanh et al. [17]Digilio et al. [15]Kratz et al. [16]Sarkozy et al. [12]Sarkozy et al. [12]
Sex/Age at DxM/6 yF/4 yM/33 yM/4 yM/5 y?/<1 yF/39 y?/<1 yM/<1 yF/2 yF/34 y
InheritancePaternalPaternaln/aPaternalSporadicn/an/an/aSporadicMaternaln/a
Common features of NS
Dysmorphic facial featuresNegNegNegPos
(mild: hypertelorism, slightly low-set, posteriorly rotated ears)
Pos
(mild: slightly macrocephaly, hypertelorism, mild ptosis, downslanting palpebral fissures, low-set and angulated ears)
Pos
(full)
Pos
(mild)
PosNegPos
(full)
Pos
(full)
Cardiac abnormalitiesNegNegNegNegPos
(PVS)
Pos
(AR)
NegPos
(HCM)
Pos
(HCM)
Pos
(HCM)
Pos
(HCM)
Growth delay/short
stature
Pos
(25th percentile)
Pos
(5–10th percentile)
Pos
(5th percentile)
NegPos
(<3th percentile)
NegNegNegn/an/an/a
Pectus deformityNegNegNegNegPosNegNegn/aNegn/an/a
Multiple LentiginesNegNegNegNegNegPosPosPosn/aNegNeg
CryptorchidismNegNegNegNegPosNegNegn/an/an/an/a
Infrequent features of NS
Sensorineural hearing lossNegNegNegPosNegNegPosNegNegNegNeg
Hematologic abnormalitiesNegNegNegNegNegNegNegNegPos
(JMML)
NegNeg
Skeletal anomaliesNegNegNegNegn/aNegNegn/aNegn/an/a
Cafe-au-lait maculesNegNegNegNegNegPosPosPosn/aPosNeg
Developmental delay/intellectual disabilityPosNegNegNegPosNegNegn/an/aPosPos
Dx, diagnosis; M, male, F, female; y, year; PVS, pulmonic valve stenosis; HCM, hypertrophic cardiomyopathy, AR, aortic regurgitation; JMML, juvenile myelomonocytic leukemia; n/a, not available.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Han, J.Y.; Park, J. Paternally Inherited Noonan Syndrome Caused by a PTPN11 Variant May Exhibit Mild Symptoms: A Case Report and Literature Review. Genes 2024, 15, 445. https://doi.org/10.3390/genes15040445

AMA Style

Han JY, Park J. Paternally Inherited Noonan Syndrome Caused by a PTPN11 Variant May Exhibit Mild Symptoms: A Case Report and Literature Review. Genes. 2024; 15(4):445. https://doi.org/10.3390/genes15040445

Chicago/Turabian Style

Han, Ji Yoon, and Joonhong Park. 2024. "Paternally Inherited Noonan Syndrome Caused by a PTPN11 Variant May Exhibit Mild Symptoms: A Case Report and Literature Review" Genes 15, no. 4: 445. https://doi.org/10.3390/genes15040445

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop